Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Open Vet J. 2021; 11(3): 458-467


Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner

Robert Philip Lavan,Robert Armstrong,Hannah Newbury,Dorothy Normile,Celine Hubinois.




Abstract
Cited by 1 Articles

Abstract
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in cats.
Aim: To assess the experiences of cat owners in the U.S., U.K., or France with flea and tick control, specifically to determine the impact of 12-week fluralaner dosing on user satisfaction, product preference, and adherence to dosing recommendations compared to flea and tick medications administered monthly.
Methods: Clients of participating veterinary practices in the U.S., U.K., or France who were visiting the clinic for a routine wellness visit and currently treating their cat with fluralaner (Bravecto®) were asked to complete a short two-page survey about their experience with flea and tick medications including fluralaner and other products they may have administered.
Results: Owners in the U.S. (451 cats), U.K. (512 cats), and France (520 cats) completed surveys. Most cat owners (66-75%) had previously administered other flea and tick products. More than 94% of cat owners surveyed in each country were satisfied or very satisfied with fluralaner. The most frequently reported benefit of using fluralaner was the 12-week dosing interval, selected by 76% of respondents in the U.S., 82% in the U.K., and 70% in France. 79-88% of cat owners (depending on country) thought that dosing with extended duration fluralaner was more convenient than dosing with monthly flea and tick products and 86-89% of cat owners that had used other flea and tick products preferred fluralaner over the other flea and tick products.
Conclusion: Veterinarians in the US, UK and France recommended 12 months of flea protection and 9-11 months of tick protection per year, even though, in this study, cat owners usually purchased 1-3 months of protection per year. A longer flea and tick dosing interval, as seen with fluralaner, correlates with higher user satisfaction and preference among cat owners. Owners identified the 12-week dosing interval and single dose efficacy as the top reasons for selecting the fluralaner product for their cat. In all three countries, most cat owners indicated that they were more likely to deliver doses of extended duration fluralaner on time, compared to flea and tick products dosed monthly.

Key words: Cats, Ectoparasites, Fleas, Fluralaner, Ticks






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.